We enrolled 77% of a global Phase 2A study in the breast cancer community, through deep advocacy partnerships and precision digital, while cutting screen-fail rates by half.

Breast cancer clinical trial recruitment built on advocacy. We hand your sites enrollment-ready patients.

Talk to our breast cancer teamSee how it works →
37
Patients enrolled (over 15+ months)
50%+
Reduction in screen-fail rate
20+
Advocacy campaigns launched
9
Clinical sites (US + Australia)

Understanding Breast Cancer as a Clinical Trial Indication

Breast cancer is the most commonly diagnosed cancer among women worldwide, and roughly one in eight women in the United States will develop invasive breast cancer in her lifetime. It is also one of the most heavily researched indications: hundreds of breast cancer trials recruit at any given time, segmented across hormone-receptor-positive, HER2-positive, and triple-negative disease, by line of therapy, and by an expanding set of biomarkers. For a sponsor, that scale is a double-edged sword: the patient pool is large, but eligible patients are stratified into narrow subgroups and are often fielding several trial options at once.

Reaching the right patients, and earning their trust, is the real constraint. Outcomes and trial participation are not evenly distributed: Black women in the US face higher breast cancer mortality, and several patient groups remain under-represented in research relative to their share of the disease. Generic digital advertising and list-purchase outreach underperform here. Patients engage with research when it reaches them through the advocacy organizations and peer communities they already trust, not through cold campaigns.

Leapcure recruits within the breast cancer community through those trusted channels. In a completed Phase 2A study among breast cancer patients (recruiting people affected by breast-cancer-related lymphedema), Leapcure's advocacy-led, digitally supported model enrolled 37 patients, 77% of the entire global study, across nine sites in the US and Australia, while reducing the screen-fail rate by more than half. The same community access and patient-success model applies across breast cancer protocols.

The Challenge

Breast cancer trial recruitment demands more than reach. It demands the right relationships.

A large, competitive trial landscape means reach alone doesn't convert

Hundreds of breast cancer trials recruit simultaneously, and eligible patients are stratified into narrow subgroups: by receptor status, line of therapy, and biomarker. Patients often weigh several options at once. Standing out requires being embedded in the communities patients already trust, not buying more impressions.

In a completed Phase 2A study within the breast cancer community, Leapcure's advocacy-led channel mix enrolled 77% of the entire global study (37 of 48 patients) across the US and Australia.

Complex eligibility creates screening failure before enrollment begins

Breast cancer eligibility is shaped by subtype, prior treatment, biomarker status, and disease stage. These criteria are specific enough that most interested patients fail screening unless candidates are matched to the protocol before site referral. Passing unqualified patients to sites wastes coordinator time and inflates screen-fail rates that slow the study.

Leapcure pre-screens against protocol eligibility and educates patients before any site referral, the approach that drove a 50%+ reduction in screen-fail rate on the Phase 2A program.

Multi-country breast cancer trials stall when site engagement is inconsistent

Breast cancer trials are typically multi-national, and site capacity, advocacy access, and referral patterns vary by region. When one country falls behind, the program slows; when several do, it is at risk.

In the Phase 2A program, Leapcure maintained active enrollment across nine sites in the US and Australia, rebalancing channel mix weekly per region and accelerating to ~4 patients/month at peak.

Advocacy is the right strategy, but execution requires real relationships

Sponsors running breast cancer studies know advocacy-led outreach outperforms generic digital. The challenge is finding a partner with established, trusted relationships in the breast cancer community, not vendors who buy list access or run one-off email blasts to advocacy members.

Leapcure launched 20+ advocacy campaigns on the Phase 2A program with named breast cancer and lymphatic-network partners, relationships that are active and co-developed, not purchased.

Three Channels. One Advocacy-Led Strategy for Your Breast Cancer Trial.

Every breast cancer study is different. Leapcure deploys the right mix of advocacy, precision digital, and patient support, mapped to your protocol, your sites, your geographies, and your timeline.

1

Activate the right advocacy and digital channels for your protocol

Leapcure activates breast cancer advocacy community outreach (named breast cancer and lymphatic-network partners), precision digital campaigns (search, Meta, and platform-native advocacy content, mapped to geography and site proximity), and a patient-support model that keeps referred patients engaged through enrollment. Channel mix is adapted to subtype, line of therapy, site locations, and eligibility criteria.

2

Pre-screen and educate before site referral

Every patient is engaged by Leapcure's team before being assigned to a site. We assess protocol eligibility, account for subtype and prior-treatment criteria, and confirm patients understand what participation involves. Caregivers and family are included where relevant. Sites conduct official screening; Leapcure ensures the patients who arrive are informed and prepared, not referrals that create coordinator work.

3

Optimize in real time based on site engagement

Channel performance and site contact rates are tracked continuously across regions. Advocacy, digital, and patient-support contributions are rebalanced by referral quality, site intake capacity, and protocol progress. On the Phase 2A program this sustained enrollment over 15+ months and enrolled 77% of the global study.

Phase 2A Recruitment in the Breast Cancer Community, Completed. 77% of the Global Study Enrolled.

Challenge Context

Indication

Breast-cancer-related lymphedema (post-surgical), Phase 2A, a study recruiting within the breast cancer patient community

Sites

9 clinical sites across the US and Australia

Challenge

Rare-disease enrollment dynamics made site-based recruitment alone insufficient to hit timelines on a 48-patient global study; dispersed patient population; multi-country site coordination (US + AU); access to the breast cancer community required to reach and engage eligible patients.

Channels Deployed

20+ advocacy campaigns launched globally with named breast cancer and lymphatic-network partners; precision digital ads; patient-success engagement; plus site-selection support.

Results & Metrics

Study-Level Result

Leapcure enrolled 37 patients (77% of the entire global Phase 2A study) via digital ads and patient success, in addition to site-selection support.

Pace

~2.5 patients/month sustained over 15+ months, accelerating to ~4/month at peak (65% of enrollments occurred in the peak year).

Screen-Fail Rate

50%+ reduction in screen-fail rate vs. the program baseline. Note: screen-fail outcomes vary by protocol. This reflects this program's requirements, not a guaranteed rate.

Referral Efficiency

Sustained, advocacy-led and site-supported engagement kept patient identification and readiness ahead of site screening as sites came online.

Patient Quality

Patients arrived informed and ready for official screening, reducing coordinator burden relative to generic digital recruitment.

Sponsor Attribution

Leading biotech sponsor, Phase 2A

Four Channels. Built for Breast Cancer. Active Before Your Trial Opens.

Leapcure reaches breast cancer patients through advocacy community outreach, precision digital, and a patient-support model, plus a fourth channel most recruitment vendors don't offer: making your trial discoverable in AI search.

Channel 1: Breast Cancer Advocacy Network

  • •Active, named partnerships across breast cancer and lymphatic-network organizations (including SHARE, Young Survival Coalition, METAVIVOR, Breast Cancer Network Australia, and Cancer Hope Network), plus community networks competitors don't have on their radar.
  • •Content co-developed with advocacy partners positions research as a trusted option, not an unsolicited pitch. Patients hear about trials from sources they already trust.
  • •Outreach designed to reach broader, historically under-represented breast cancer populations through the communities they trust.

Channel 2: Precision Digital Campaigns

  • •Search, Meta (Facebook/Instagram), and platform-native advocacy content optimized for breast cancer patient populations and targeted by geography, subtype, and site proximity.
  • •Digital is mapped to site capacity in real time across regions. Referrals are modulated so sites aren't overwhelmed and patient quality holds.
  • •Digital supports advocacy rather than replacing it; it fills gaps where community channels are thin.

Channel 3: Patient Support Model

  • •Every referred patient gets step-by-step guidance from first contact through enrollment, accounting for treatment burden, scheduling, and the emotional weight of a breast cancer diagnosis.
  • •Caregivers and family are included where relevant; breast cancer participation decisions often involve a support network.
  • •Patient support is the mechanism behind the 50%+ screen-fail reduction on the Phase 2A program; it's why sites receive enrollment-ready patients.

Channel 4: AEO and AI-Search Visibility for Your Trial

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview questions like "what breast cancer trials am I eligible for?" Most recruitment vendors don't structure for this.
  • •Leapcure makes your trial's information genuinely retrievable by AI engines: published as crawlable, server-rendered HTML; made factually rich with unique first-party detail; and placed in the trusted sources AI engines actually cite: advocacy-org pages and ClinicalTrials.gov.
  • •This is honest AEO, not schema tricks, AI-specific markup, or "structuring for AI." As AI search grows as a patient-discovery path, a genuinely citable trial presence compounds over the life of your study.

Built on Trusted Relationships in the Breast Cancer Community

Leapcure's breast cancer advocacy partnerships are active, named, and co-developed, not list purchases.

SHARE Cancer Support

Peer support for women facing breast and ovarian cancer

Young Survival Coalition

The leading org for young adults diagnosed with breast cancer

METAVIVOR

Funds metastatic breast cancer research; led by patients

Breast Cancer Network Australia

Australia's peak breast cancer consumer organization; anchors our AU reach

Cancer Hope Network

One-on-one support matching patients with trained survivors

The Cancer Couch Foundation

Patient-founded metastatic breast cancer research funder

MBC-focused trial alert network

Connects metastatic breast cancer patients to studies and trials

LERN (Lymphatic Education & Research Network)

Research and education on lymphatic disease; channel for the lymphedema proof study

National Lymphedema Network

National lymphedema patient and clinician network

Lighthouse Lymphedema Network

Community support for people living with lymphedema

The Lymphie Life

Patient-founded lymphedema community platform

Living with breast cancer? A clinical trial may be an option.

If you're living with breast cancer, a clinical trial may give you access to investigational treatments not yet widely available. We know that weighing research options can feel overwhelming, especially alongside treatment, appointments, and everything else a diagnosis brings. Leapcure's team provides step-by-step support, and we include your family or caregivers wherever that's helpful.

See if a breast cancer trial may be right for you
Leapcure kangaroo mascot

Leapcure's breast cancer recruitment team has completed a Phase 2A program in the breast cancer community, enrolling 77% of the global study across the US and Australia and cutting screen-fail by more than half. We deploy advocacy, precision digital, patient support, and AEO / AI-search channels adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our breast cancer team